IonMed, an Israeli company that develops plasma-based technology, has received CE Mark clearance for its Bioweld1 cold plasma system for surgical incision closure.
Israel is not just at the forefront of high tech, but also medical tech. Israeli doctors and researchers have been winning awards including Nobel Prizes for their medical breakthroughs. The country’s medical business sector has been almost as successful as its high tech sector.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
One important area in medical treatment is that of closing up a patient after an operation. The reason why a specialist is need to handle the anesthesia is that the longer someone is under the more likely that complications could arise. This is why doctors look for ways to speed up the process of closing.
IonMed is a portfolio company of The Trendlines Group and of Generali Financial Holdings Fund. It is developing and commercializing non-thermal (cold) plasma technology to enhance surgical wound closure and wound healing.
Bioweld, the company boasts, is the first system in the rapidly emerging field of plasma medicine designed for use in operating room settings as an alternative to surgical staples, sutures and sealants.
“The use of cold plasma holds enormous promise as a new therapeutic paradigm in wound care, and more broadly in medicine, ” said Shai Levanon, CEO of IonMed. “With the CE Mark clearance of Bioweld1, our first system, we have achieved important validation for our technology, a key milestone for the company, and a significant step towards commercialization.” He added that IonMed expects to select a distribution partner and begin commercializing the system in the EU in 2015.
The patented Bioweld1 system combines a plasma generating device, including a disposable plasma emitting head and a medical plaster, Chitoplast™, which covers the wound and assists in approximating the incision edges.
To seal the incision and promote coagulation and healing, the Chitoplast ‘solder’ is affixed to the incision edges, and the plasma jet is applied along the incision edge. Chitoplast consists of adhesive plaster strips and a film, based on chitin, a natural biomaterial with established hemostatic and antimicrobial properties.
The CE Mark clearance is based on positive preclinical as well as clinical studies, including a trial of 20 women undergoing elective cesarean section and a pilot human evaluation of skin grafting. Other studies in preclinical models have documented safety, rapid disinfection, and efficacy in skin graft closure.
